Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hematologic Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00512083
What this trial is testing

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid
Antisoma Research 70
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Testing effectiveness (Phase 2)Study completedNCT00216697
What this trial is testing

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 13
Early research (Phase 1)Study completedNCT00349596
What this trial is testing

Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Who this might be right for
Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT01745640
What this trial is testing

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Who this might be right for
Multiple Myeloma
University Hospital, Lille 63
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Testing effectiveness (Phase 2)Study completedNCT01363297
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Pfizer 72
Testing effectiveness (Phase 2)UnknownNCT00800059
What this trial is testing

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Who this might be right for
Multiple Myeloma
Ottawa Hospital Research Institute 27
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Early research (Phase 1)Active Not RecruitingNCT04606433
What this trial is testing

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd. 47
Early research (Phase 1)Study completedNCT02096289
What this trial is testing

Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Ontario Clinical Oncology Group (OCOG) 13
Testing effectiveness (Phase 2)Ended earlyNCT05886491
What this trial is testing

GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia
Takeda 16
Testing effectiveness (Phase 2)Study completedNCT01702155
What this trial is testing

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic Leukemia
Delta-Fly Pharma, Inc. 69
Early research (Phase 1)Study completedNCT03181126
What this trial is testing

Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Lymphoblastic Lymphoma
AbbVie 69
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Ended earlyNCT05117008
What this trial is testing

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin 1
Early research (Phase 1)Ended earlyNCT02137889
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Who this might be right for
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Novartis Pharmaceuticals 3
Not applicableStudy completedNCT03098589
What this trial is testing

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Who this might be right for
Lymphoma
Celgene 1,149
Early research (Phase 1)Study completedNCT03733717
What this trial is testing

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sanofi 25
Testing effectiveness (Phase 2)WithdrawnNCT04354025
What this trial is testing

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Washington University School of Medicine
Next Page